Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel

Supporting evidence

• Review decision

• Review decision – January 2019

• Review decision paper (PDF 375 KB)

  Published:

  07 February 2019

• Matrix of stakeholders (PDF 267 KB)

  Published:

  07 February 2019

• Evaluation report

• Appraisal consultation committee papers (PDF 4.72 MB)

  Published:

  25 May 2016

• Final appraisal determination committee papers (PDF 610 KB)

  Published:

  25 May 2016